Cornea · 2009
Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oh Joo Youn, Kim Mee Kum, Wee Won Ryang
Аннотация
PURPOSE: The purpose of this study was to evaluate the efficacy and safety of subconjunctival and corneal intrastromal bevacizumab injections on corneal neovascularization in patients with lipid keratopathy.
METHODS: Three eyes of 3 patients with lipid keratopathy accompanied by corneal neovascularization received at least 2 subconjunctival and corneal intrastromal injections of bevacizumab (1.25 mg/0.05 mL, respectively) at 1-month intervals. Ophthalmic examinations, including visual acuity, tonometry, slit lamp biomicroscopy, and corneal topography, were performed before injection and every month thereafter.
RESULTS: All patients had marked regression of corneal neovascularization. Reduction in lipid deposition was noted in one patient. There were no adverse ocular or systemic events, except for a small intracorneal hemorrhage noted in one patient, which quickly and spontaneously cleared.
CONCLUSION: Subconjunctival and intracorneal bevacizumab is a well-tolerated and effective method for obliterating corneal neovascularization in lipid keratopathy.
METHODS: Three eyes of 3 patients with lipid keratopathy accompanied by corneal neovascularization received at least 2 subconjunctival and corneal intrastromal injections of bevacizumab (1.25 mg/0.05 mL, respectively) at 1-month intervals. Ophthalmic examinations, including visual acuity, tonometry, slit lamp biomicroscopy, and corneal topography, were performed before injection and every month thereafter.
RESULTS: All patients had marked regression of corneal neovascularization. Reduction in lipid deposition was noted in one patient. There were no adverse ocular or systemic events, except for a small intracorneal hemorrhage noted in one patient, which quickly and spontaneously cleared.
CONCLUSION: Subconjunctival and intracorneal bevacizumab is a well-tolerated and effective method for obliterating corneal neovascularization in lipid keratopathy.
Предметные рубрики MeSH
AdultAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabConjunctivaCorneal NeovascularizationCorneal StromaCorneal TopographyFemaleHumansInjectionsIntraocular PressureLipid Metabolism DisordersMaleMiddle AgedPhospholipidsTonometry, OcularVascular Endothelial Growth Factor AVisual Acuity